Results 71 to 80 of about 260,883 (251)

Characterization of Anticholinergic Medication Use and Its Associations With Everyday Memory Problems and Cognitive Decline in Autistic Adults With Higher Support Needs

Autism Research, EarlyView.
ABSTRACT Among older adults in the general population, medications with anticholinergic (AC) effects are associated with declines in cognitive functioning and with dementia and Alzheimer's disease. Autistic people have high rates of co‐occurring medical conditions and polypharmacy across the lifespan; thus, they may be at particularly high risk of ...
Goldie A. McQuaid, Nancy Raitano Lee, Gregory L. Wallace   +2 more
wiley   +1 more source

Ethical Issues in Delivering Psychological Therapies in Geriatric Psychiatry in India

Indian Journal of Psychological Medicine, 2021
Sridhar Vaitheswaran, Suhavana Balasubramanian, Nirupama Natarajan, Shreenila Venkatesan, Nivedhitha Srinivasan, Gayathri Nagarajan, Vaishnavi Ramanujam, Subashini Sargunan   +7 more
doaj   +1 more source

Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method

NeuroImage: Clinical, 2019
Background: Mismatch negativity (MMN) is a measure of pre-attentive auditory information processing related to change detection. Traditional scalp-level EEG methods consistently find attenuated MMN in patients with chronic but not first-episode ...
M. Randau, B. Oranje, M. Miyakoshi, S. Makeig, B. Fagerlund, B. Glenthøj, N. Bak   +6 more
doaj   +1 more source

Immunology of Schizophrenia [PDF]

Neuroimmunomodulation, 2014
Increased proinflammatory markers like cytokines have been described in the blood and cerebrospinal fluid of patients suffering from schizophrenia. Animal models have shown that a hit in early life to the immune system might trigger a lifelong increased immune reactivity.
openaire   +3 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Exploring new avenues: Psychedelic‐assisted therapy for young people

British Journal of Clinical Pharmacology, EarlyView.
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including ...
Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J. Nutt, Martina Di Simplicio   +3 more
wiley   +1 more source

Soluble urokinase plasminogen activator receptor – What are the clinical potentials in psychiatry?

Brain, Behavior, & Immunity - Health
Background: Mental disorders have been associated with systemic chronic inflammation, and conditions such as depression and schizophrenia are increasingly linked to inflammatory processes.
Franziska Grundtvig Huber, Milo Wolfgang Pilgaard Kristensen, Mette Ødegaard Nielsen, Torkel Vang, Jimmi Nielsen   +4 more
doaj   +1 more source

The quantification and epistemology of medicines use and polypharmacy tested in an observational study

British Journal of Clinical Pharmacology, EarlyView.
Definitions of ‘medicines use’ and ‘polypharmacy’ may refer to all medicines, regular long‐term medicines or another subset. Valid definitions of medicines use should incorporate type of use (long term, short course and as needed [PRN]), changes in use (start, stop and dose change) and a description of temporal examination (cross‐sectional or ...
Lorna Pairman, Paul Chin, Matthew Doogue
wiley   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

British Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask, Miina Lamminmäki, Olli Kampman, Mari Hämäläinen, Eeva Moilanen, Niko Seppälä, Anssi Solismaa   +6 more
wiley   +1 more source

Schizophrenia [PDF]

BMJ, 2007
Picchioni, M M, Murray, R M
openaire   +3 more sources